Quintrio
Home

Stock overview

Psyence Biomedical Ltd. Common Shares

PBM

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.60 – $2.96
Volume 40,824
Market cap $11M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PBM.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PBM.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs has exercised its put option rights, resulting in a Share-for-Share Exchange where Psyence will issue 1,146,159 common shares valued at $5 million to acquire 2,900 PsyLabs shares. Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed. The deal is expected to close on February 25, 2026, and aims to strengthen supply chain security for pharmaceutical-grade psychedelic compounds as the company advances its clinical programs.

GlobeNewswire Inc.

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence BioMed's board has ratified a put option agreement with PsyLabs, a leading pharmaceutical-grade psychedelic manufacturer. The agreement grants PsyLabs the right to require Psyence to make further equity investments while securing reliable supply of pharmaceutical-grade psychedelics for clinical and commercial programs. The structure preserves Psyence's near-term financial flexibility while advancing its development pathway.

GlobeNewswire Inc.

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its 1-for-6.25 reverse stock split will become effective on February 2, 2026, after being delayed from its original January 20 date. The consolidation will reduce outstanding shares from 6,388,604 to 1,022,177. The company's shares will continue trading under the symbol 'PBM' with a new CUSIP number.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 2, 20261-for-6.25reverse split
May 5, 20251-for-7.97reverse split
Nov 26, 20241-for-75reverse split